FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to producing a population of collagen II-specific Tr1-cells, and can be used in medicine. The population of collagen II-specific Tr1-cells with the quiescent phenotype of CD4+CD25-FoxP3- is recovered. The produced population of Tr1-cells combined with one or more pharmaceutically acceptable carriers are used as an ingredient of a pharmaceutical composition for treating arthritis.
EFFECT: invention enables producing the effective agent for treating arthritis.
12 cl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| Tr1 CELLS, MESENCHYMAL STEM CELLS AND USING THEM | 2008 |
|
RU2493869C2 |
| COMPOSITIONS TO TREAT INFLAMMATORY BOWEL CONDITION | 2008 |
|
RU2495121C2 |
| METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY | 2010 |
|
RU2610427C2 |
| METHODS FOR IDENTIFICATION, SELECTION, ENRICHMENT AND DEPLETION OF Tr1 CELLS POPULATIONS, Tr1 CELLS POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR THERAPY EFFECT MONITORING | 2011 |
|
RU2627445C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| ANTIBODY OR ITS ANTI-BINDING FRAGMENT, WHICH IS CAPABLE TO BE BOUND USING THE INTERLEUKIN-6 HUMAN RECEPTOR | 2016 |
|
RU2656160C2 |
| THERAPEUTIC AGENTS AND AUTOIMMUNE DISEASES | 1996 |
|
RU2203088C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| NEW SUBPOPULATION OF TREG CD8CD45RC CELLS AND ITS APPLICATIONS | 2016 |
|
RU2766691C2 |
